The effect of ezetimibe and acarbose in treatment of non alcoholic fatty liver disease

Comparison the effect of ezetimibe and acarbose on biochemical indices in patient with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201109197590N1

Enrollment

Registered

2011-12-23

Start date

2011-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic fatty liver disease. Fatty (change of) liver

Interventions

Intervention 1: 50 mg acarbose 3 times per day, oral, in acarbose group. Intervention 2: 10 mg ezetimibe once per day, oral, in ezetimibe group.

Treatment - Drugs

50 mg acarbose 3 times per day, oral, in acarbose group

10 mg ezetimibe once per day, oral, in ezetimibe group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- the patients diagnosed by means of ultrasound (Bright liver pattern with liver kidney contrast); 2-ALT more than 40 in men and more than 31 in women; 3-Age above18. Exclusion criteria: 1-Type1 or 2 diabetes mellitus; 2-Positive serology for hepatitis; 3-Alcohol consumption more than 20gr per day; 4-History of renal or liver disease; 5-Using drugs like steroids or drugs that influence energy metabolism, intestinal transit, substrate metabolism.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver enzyme, AST, aspartate aminotransferase. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.;Liver enzyme, ALT, alanine aminotransferase. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.	—

Secondary

Measure	Time frame
Insulin resistance index. Timepoint: Before and 2months after treatment. Method of measurement: Fasting glycemia mmol/L× fasting insulinemiaMIU/L/22 .lab kit.;Inflamation index hs CRP. Timepoint: Before and 2 months after treatment. Method of measurement: Lab kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForoogh Alborzi Avanaki

Qazvin University of Medical Sciences

foroogh1983@yahoo.com+98 28 1333 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026